Oxidative stress and Alzheimer disease: Where do we stand?

Current Alzheimer Research

Volumn 13, Issue 2, 2016, Pages 108-111

  Barone, Eugenio ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BILIVERDIN; HEME OXYGENASE; METHIONINE;

ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; DISEASE COURSE; HUMAN; NITROSATIVE STRESS; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; ANIMAL; DRUG EFFECTS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; HUMANS; OXIDATIVE STRESS;

EID: 84959377101     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720501302160101123849     Document Type: Article

References (44)

1. Martins RN, Harper CG, Stokes GB, Masters CL. Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer’s disease may reflect oxidative stress. J Neurochem 46(4): 1042-5 (1986).
2. Butterfield DA, Swomley AM, Sultana R. Amyloid beta-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxidants & redox signaling 19(8): 823-35 (2013).
3. De Felice FG. Alzheimer’s disease and insulin resistance: translating basic science into clinical applications. J Clin Investig 123 (2): 531-9 (2013).
4. Wang X, Wang W, Li L, Perry G, Lee HG, Zhu X. Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease. Biochimica et biophysica acta 1842(8): 1240-7 (2014).
5. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, et al. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. ProcNat Acad Sci USA 91(8): 3270-4 (1994).
6. Butterfield DA, Galvan V, Lange MB, Tang H, Sowell RA, Spilman P, et al. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid betapeptide of APP. Free Radical Biol Med 48 (1): 136-44 (2010).
7. Butterfield DA, Drake J, Pocernich C, Castegna A. Evidence of oxidative damage in Alzheimer’s disease brain: central role for amyloid beta-peptide. Trends Mol Med 7 (12): 548-54 (2001).
8. Markesbery WR. Oxidative stress hypothesis in Alzheimer’s disease. Free Radical Biol Med 23 (1): 134-47 (1997).
9. Butterfield DA, Kanski J. Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer’s amyloid beta-peptide 1-42. Peptides 23(7): 1299-309 (2002).
10. Ripoli C, Piacentini R, Riccardi E, Leone L, Li Puma DD, Bitan G, et al. Effects of different amyloid beta-protein analogues on synaptic function. NeurobiolAging 34(4): 1032-44 (2013).
11. Di Domenico F, Barone E, Perluigi M, Butterfield DA. Strategy to reduce free radical species in Alzheimer’s disease: an update of selected antioxidants. ExpRev Neurotherap 15 (1): 19-40 (2015).
12. Behl C. Amyloid beta-protein toxicity and oxidative stress in Alzheimer’s disease. Cell Tissue Res 290(3): 471-80 (1997).
13. Varadarajan S, Yatin S, Aksenova M, Butterfield DA. Review: Alzheimer’s amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol 130 (2-3): 184-208 (2000).
14. Butterfield DA, Gu L, Di Domenico F, Robinson RA. Mass spectrometry and redox proteomics: applications in disease. Mass Spectrom Rev 33(4): 277-301 (2014).
15. Tomic JL, Pensalfini A, Head E, Glabe CG. Soluble fibrillar oligomer levels are elevated in Alzheimer’s disease brain and correlate with cognitive dysfunction. Neurobiol Dis 35(3): 352-8 (2009).
16. Sultana R, Butterfield DA. Role of oxidative stress in the progression of Alzheimer’s disease. J Alzheimer Dis 19 (1): 341-53 (2010).
17. Belanger M, Allaman I, Magistretti PJ. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metabol 14(6): 724-38 (2011).
18. Benzi G, Moretti A. Age-and peroxidative stress-related modifications of the cerebral enzymatic activities linked to mitochondria and the glutathione system. Free Radical Biol Med 19 (1): 77-101 (1995).
19. Sultana R, Piroddi M, Galli F, Butterfield DA. Protein levels and activity of some antioxidant enzymes in hippocampus of subjects with amnestic mild cognitive impairment. Neurochem Res 33 (12): 2540-6 (2008).
20. Mangialasche F, Xu W, Kivipelto M, Costanzi E, Ercolani S, Pigliautile M, et al. Tocopherols and tocotrienols plasma levels are associated with cognitive impairment. Neurobiol Aging 33 (10): 2282-90 (2012).
21. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer’s disease. Neurobiol Aging 24(7): 915-9 (2003).
22. Zhao Y, Zhao B. Oxidative stress and the pathogenesis of Alzheimer’s disease. Oxid Med Cell longevity 2013: 316523 (2013).
23. Guix FX, Wahle T, Vennekens K, Snellinx A, Chavez-Gutierrez L, Ill-Raga G, et al. Modification of gamma-secretase by nitrosative stress links neuronal ageing to sporadic Alzheimer’s disease. EMBO Mol Med 4(7): 660-73 (2012).
24. Tan JL, Li QX, Ciccotosto GD, Crouch PJ, Culvenor JG, White AR, et al. Mild oxidative stress induces redistribution of BACE1 in non-apoptotic conditions and promotes the amyloidogenic processing of Alzheimer’s disease amyloid precursor protein. PloS one 8(4): e61246 (2013).
25. Chen L, Na R, Gu M, Richardson A, Ran Q. Lipid peroxidation upregulates BACE1 expression in vivo: a possible early event of amyloidogenesis in Alzheimer’s disease. J Neurochem 107 (1): 197-207 (2008).
26. Gwon AR, Park JS, Arumugam TV, Kwon YK, Chan SL, Kim SH, et al. Oxidative lipid modification of nicastrin enhances amyloidogenic gamma-secretase activity in Alzheimer’s disease. Aging Cell 11(4): 559-68 (2012).
27. Arimon M, Takeda S, Post KL, Svirsky S, Hyman BT, Berezovska O. Oxidative stress and lipid peroxidation are upstream of amyloid pathology. Neurobiol Dis (2015).
28. Mecocci P, Polidori MC. Antioxidant clinical trials in mild cognitive impairment and Alzheimer’s disease. Biochimica et biophysica acta 1822(5): 631-8 (2012).
29. Mancuso C, Siciliano R, Barone E, Preziosi P. Natural substances and Alzheimer’s disease: from preclinical studies to evidence based medicine. Biochimica et biophysica acta 1822(5): 616-24 (2012).
30. Barone E, Di Domenico F, Mancuso C, Butterfield DA. The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it’s time for reconciliation. Neurobiol Dis 62: 144-59 (2014).
31. Gozzelino R, Jeney V, Soares MP. Mechanisms of cell protection by heme oxygenase-1. Ann Rev Pharmacol Toxicol 50: 323-54 (2010).
32. Kapitulnik J, Maines MD. Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin. Trends Pharmacol Sci 30(3): 129-37 (2009).
33. Barone E, Mancuso C, Di Domenico F, Sultana R, Murphy MP, Head E, et al. Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease. J Neurochem 120 (1): 135-46 (2012).
34. Butterfield DA, Barone E, Di Domenico F, Cenini G, Sultana R, Murphy MP, et al. Atorvastatin treatment in a dog preclinical model of Alzheimer’s disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain. The international journal of neuropsychopharmacology/official scientific journal of the Collegium Internationale Neuropsychopharmacologicum 15(7): 981-7 (2012).
35. Opii WO, Joshi G, Head E, Milgram NW, Muggenburg BA, Klein JB, et al. Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer’s disease. Neurobiol Aging 29 (1): 51-70 (2008).
36. Di Domenico F, Pupo G, Giraldo S, Lioret A, Badia MC, Schinina ME, et al. Autoantibodies profile in matching CSF and serum from AD and aMCI patients: potential pathogenic role and link to oxidative damage. Curr Alzheimer Res 13(2): 112-122 (2016).
37. Serini S, Calviello G. Reduction of oxidative/nitrosative stress in brain and its involvement in the neuroprotective effect of n-3 PUFA in Alzheimer’s disease. Curr Alzheimer Res 13(2): 123-134 (2016).
38. Hannibal L. Nitric Oxide Homestasis in Neurodegenerative Diseases. Curr Alzheimer Res 13(2): 135-149 (2016).
39. Bell MC, Meier SE, Ingram AL, Abisambra JF. PERK-opathies: an endoplasmic reticulum stress mechanism underlying neurodegeneration. Curr Alzheimer Res 13(2): 150-163 (2016).
40. Cenini G, Voos W. Role of Mitochondrial Protein Quality Control in Oxidative Stress-induced Neurodegenerative Diseases Curr Alzheimer Res 13(2): 164-173 (2016).
41. Gozzelino R. The Pathophysiology of Heme in the Brain. Curr Alzheimer Res 13(2): 174-184 (2016).
42. Cassano T, Pace L, Bedse G, Lavecchia AM, De Marco F, Gaetani S, et al. Glutamate and mitochondria: two prominent players in the oxidative stress-induced neurodegeneration. Curr Alzheimer Res 13(2): 185-197 (2016).
43. Giudetti AM, Romano A, Lavecchia AM, Gaetani S. The role of brain cholesterol and its oxidized products in Alzheimer’s disease. Curr Alzheimer Res 13(2): 198-205 (2016).
44. Lloret A, Fuchsberger T, Giraldo E, Vina J. Reductive stress: A new concept in Alzheimer’s disease. Curr Alzheimer Res 13(2): 206-211 (2016).